Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology
Schlieren (Zurich), Switzerland, February 11, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders. Under the agreement Kuros will supply the bone graft in various forms and SeaSpine will market the products under the brand name OsteoCurrent in the U.S. and other select markets in Europe, South America and the Middle East providing the necessary regulatory approvals are achieved. Initial sales in the U.S. are expected prior to the end of H1 2019. Terms of the agreement were not disclosed.
Kuros’s proprietary bone graft technology comprises biphasic calcium phosphate with an advanced
submicron surface topography that directs bone formation after implantation. With its unique topography,
it preferentially directs early wound healing toward the bone-forming pathway, resulting in predictable
healing, reliable fusions and an osteoinductive claim in Europe.